Artiva's AlloNK shows 71% response in refractory rheumatoid arthritis; FDA approves Phase 3 trial start in 2026

Artiva Biotherapeutics reported positive initial clinical data for its AlloNK therapy in refractory rheumatoid arthritis (RA), showing a 71% ACR50 response rate in patients with six months follow-up. The treatment demonstrated good tolerability with no serious adverse events, supporting outpatient use in community settings. The FDA has aligned with Artiva on a Phase 3 registrational trial starting in the second half of 2026, comparing AlloNK plus rituximab against rituximab alone in about 150 refractory RA patients. This trial aims to address the significant unmet need in difficult-to-treat RA patients who have failed multiple prior therapies.